MARKET

SPPI

SPPI

Spectrum Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.51
+0.24
+3.30%
After Hours: 7.51 0 0.00% 16:45 10/11 EDT
OPEN
7.39
PREV CLOSE
7.27
HIGH
7.62
LOW
7.39
VOLUME
459.54K
TURNOVER
--
52 WEEK HIGH
14.65
52 WEEK LOW
6.22
MARKET CAP
846.98M
P/E (TTM)
-4.2864
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SPPI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SPPI News

  • Spectrum Pharma announces publication of positive poziotinib data in cancer cell
  • Seeking Alpha - Article.10/04 12:02
  • Spectrum Pharmaceuticals Announces Publication of Positive Poziotinib Data in Cancer Cell
  • Business Wire.10/04 12:00
  • Spectrum Pharma Highlights Publication Of Poziotinib Data In Cancer Cell
  • Benzinga.10/04 11:01
  • We're Hopeful That Spectrum Pharmaceuticals (NASDAQ:SPPI) Will Use Its Cash Wisely
  • Simply Wall St..10/01 19:58

More

Industry

Biotechnology & Medical Research
+0.89%
Pharmaceuticals & Medical Research
+0.89%

Hot Stocks

Name
Price
%Change

About SPPI

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
More

Webull offers Spectrum Pharmaceuticals, Inc. (SPPI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.